Sensei Biotherapeutics Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
FTH$12.92+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(6,864) | $(7,992) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 461 | 1,216 |
| Depreciation and amortization | 30 | 137 |
| Accretion on marketable securities | (257) | (114) |
| Non-cash lease expense | 411 | 370 |
| Amortization of financing lease right-of-use assets | 4 | 194 |
| Gain on asset disposal | (20) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses | (438) | (716) |
| Other assets | 57 | 56 |
| Accounts payable and accrued liabilities | 1,109 | 306 |
| Compensation and employee benefits | (1,163) | (703) |
| Operating lease liabilities | (424) | (371) |
| Other liabilities | — | 1 |
| Net cash used in operating activities | (7,094) | (7,616) |
| Investing activities | ||
| Purchases of property and equipment | — | (37) |
| Purchases of short-term investments | (6,349) | (6,259) |
| Maturities of short-term investments | 13,500 | 12,066 |
| Proceeds from sale of property and equipment | 40 | — |
| Net cash provided by investing activities | 7,191 | 5,770 |
| Financing activities | ||
| Principal payments for financing leases | (211) | (199) |
| Payment of employee restricted stock tax withholdings | (3) | (10) |
| Net cash used in financing activities | (214) | (209) |
| Net decrease in cash and cash equivalents | (117) | (2,055) |
| Cash and cash equivalents at beginning of period | 9,994 | 13,011 |
| Cash and cash equivalents at end of period | $9,877 | $10,956 |
| Supplemental disclosure of noncash financing information: | ||
| Issuance of equity in exchange for compensation included in compensation and employee benefits | $— | $293 |
| Asset disposals included in other assets | $(353) | $— |
| Initial measurement of finance lease right-of-use assets | $— | $1 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.